Morgan Stanley Reiterates Overweight on Cytokinetics, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung reiterated an Overweight rating on Cytokinetics (NASDAQ:CYTK) and maintained a $60 price target.
June 22, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Jeffrey Hung reiterated an Overweight rating on Cytokinetics and maintained a $60 price target.
The reaffirmation of the Overweight rating and maintenance of the $60 price target by Morgan Stanley analyst Jeffrey Hung indicates a positive outlook for Cytokinetics. This news is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100